About
Cellular Engineering Tools (CRISPR)
Areas of Focus
Categories
Non-PharmaceuticalStem Cell & Cellular TherapyBiotech
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
284
By Phase
PHASE1: 4
By Status
RECRUITING: 2WITHDRAWN: 1TERMINATED: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
Hover over trial bars to see details
Recent Trials
NCT06752876Lead Sponsor
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
PHASE1Withdrawn
Started: Dec 31, 2027 · Completed: Apr 30, 2029
NCT06128044Lead Sponsor
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
PHASE1Terminated
12 participants
Started: Feb 8, 2024 · Completed: May 30, 2025
NCT05722418Lead Sponsor
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
PHASE1Recruiting
50 participants
Started: Feb 6, 2023 · Completed: Dec 31, 2027
NCT05332054Lead Sponsor
Long-Term Follow-up Study
N/AEnrolling by invitation
150 participants
Started: Mar 16, 2022 · Completed: Dec 31, 2041
NCT04637763Lead Sponsor
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
PHASE1Recruiting
72 participants
Started: May 26, 2021 · Completed: Sep 30, 2025
Locations (1)
Headquarters
Berkeley, CA, United States
Map
Loading map...